A phase I/randomised phase II trial of abiraterone acetate with or without RO5503781 in patients with metastatic castration resistant prostate cancer (mCRCP) who have not previously received docetaxel
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 Feb 2019
Price : $35 *
At a glance
- Drugs Idasanutlin (Primary) ; Abiraterone; Prednisolone
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms MAdCaP
- 14 Feb 2019 Status changed from completed to active, no longer recruiting.
- 14 Feb 2019 Planned End Date changed from 28 Feb 2018 to 28 Feb 2020.
- 31 Aug 2018 Biomarkers information updated